组织诊断市场规模、份额、成长分析（按产品类型、按技术、按疾病类型、按方式、按最终用户、按地区）- 产业预测 2025-2032

2023 年全球组织诊断市场规模价值 54 亿美元，预计将从 2024 年的 58.6 亿美元成长到 2032 年的 113.5 亿美元，预测期内（2025-2032 年）的复合年增长率为 8.6%。

受癌症发病率上升的推动，组织诊断市场预计将大幅成长。由于资源被转移到控制病毒上，COVID-19 疫情导致诊断检测暂时中断，但随着医疗保健系统适应新常态，市场正在復苏。人们对准确诊断和疾病监测的需求日益增长，尤其是对癌症。解剖病理学的进步推动了临床病理学的不断扩展，解剖病理学和分子病理学的融合日益突出。液态切片在癌症诊断中的应用正在增加，计算病理学日益增长的重要性凸显了生物资讯学的重要性。在过去的二十年里，该领域的诊断工具得到了扩展，彻底改变了病理学家和临床医生的实践。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管格局
• 案例研究
• 技术分析

组织诊断市场规模（按产品类型和复合年增长率） (2025-2032)

• 市场概览
• 耗材
  • 抗体
  • 套件
  • 试剂
  • 探测
• 装置
  • 玻片染色系统
  • 扫描器
  • 组织处理系统
  • 其他仪器

组织诊断市场规模（依技术及复合年增长率） (2025-2032)

• 市场概览
• 免疫组织化学
• 原位杂交
• 原发染色及特殊染色
• 解剖病理学
• 分子病理学
• 数位病理学和工作流程管理
• 特殊染色

组织诊断市场规模（按疾病类型和复合年增长率）（2025-2032）

• 市场概览
• 乳癌
• 胃癌
• 淋巴瘤
• 摄护腺癌
• 非小细胞肺癌
• 其他的

组织诊断市场规模（按方式和复合年增长率） (2025-2032)

• 市场概览
• 临床
• 製药/CRO/研究市场

组织诊断市场规模（按最终用户和复合年增长率划分）（2025 年至 2032 年）

• 市场概览
• 医院
• 研究部门
• 製药公司
• 合约研究组织（CRO）
• 其他的

组织诊断市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• F. Hoffmann-La Roche Ltd.（Switzerland）
• Abbott Laboratories（USA）
• Thermo Fisher Scientific Inc.（USA）
• Siemens Healthineers（Germany）
• Danaher Corporation（USA）
• bioMerieux SA（France）
• QIAGEN NV（Netherlands）
• Becton, Dickinson and Company（BD）（USA）
• Merck KGaA（Germany）
• GE Healthcare（USA）
• BioGenex Laboratories（USA）
• Cell Signaling Technology, Inc.（USA）
• Bio SB（USA）
• DiaGenic ASA（Norway）
• Agilent Technologies（USA）
• Fujirebio Inc.（Japan）
• Tecan Group Ltd.（Switzerland）
• STRATEC SE（Germany）
• Seegene Inc.（South Korea）
• Leica Biosystems（Germany）

结论和建议

Global Tissue Diagnostics Market size was valued at USD 5.4 billion in 2023 and is poised to grow from USD 5.86 billion in 2024 to USD 11.35 billion by 2032, growing at a CAGR of 8.6% during the forecast period (2025-2032).

The tissue diagnostics market is poised for significant growth driven by the rising incidence of cancer. Although the COVID-19 pandemic temporarily hindered diagnostic testing due to resource allocation towards virus containment, the market is rebounding as healthcare systems adapt to new normals. The demand for precise diagnosis and disease monitoring, particularly for cancer, is escalating. Advances in anatomic pathology are fostering the continuous expansion of clinical pathology, while the integration of anatomical and molecular pathology is increasingly evident. The adoption of liquid biopsies for cancer diagnosis is rising, and the growing relevance of computational pathology emphasizes the importance of bioinformatics. Over the past two decades, the sector has seen enhanced diagnostic tools, revolutionizing the practice for pathologists and clinicians.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Tissue Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Tissue Diagnostics Market Segments Analysis

Global Tissue Diagnostics Market is segmented by Product Type, Technology, Disease Type, Modality, End-user and region. Based on Product Type, the market is segmented into Consumables and Instruments. Based on Technology, the market is segmented into Immunohistochemistry, In Situ Hybridization, Primary & Special Staining, Anatomic Pathology, Molecular Pathology, Digital Pathology & Workflow Management and Special Staining. Based on Disease Type, the market is segmented into Breast Cancer, Gastric Cancer, Lymphoma, Prostate Cancer, Non-small Cell Lung Cancer and Others. Based on Modality, the market is segmented into Clinical and Pharma / CRO / Research Market. Based on End-user, the market is segmented into Hospitals, Research Laboratories, Pharmaceutical Companies, Contract Research Organizations (CROs) and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Tissue Diagnostics Market

A significant driving force behind the expansion of the global tissue diagnostics market is the rising incidence of chronic diseases, notably cancer. With cancer rates escalating worldwide, the need for swift and precise diagnostic solutions becomes crucial, as early detection significantly increases the likelihood of successful treatment. Innovations in tissue diagnostics, such as immunohistochemistry and molecular pathology, have enhanced the ability of healthcare professionals to identify various tumor types and subtypes accurately. The growing demand for reliable diagnostic tools compels healthcare providers to invest in cutting-edge tissue diagnostics technologies, thereby fostering market growth and enhancing the quality of care for cancer patients.

Restraints in the Global Tissue Diagnostics Market

The Global Tissue Diagnostics market faces significant restraint due to the high costs associated with modern tissue diagnostic techniques. Advanced diagnostic tools and methodologies often come with substantial price tags that can be unaffordable for smaller hospitals and laboratories. The expenses related to equipment, training, and ongoing maintenance further complicate the situation. This financial barrier can hinder access to the latest diagnostic tests, particularly in developing nations where healthcare resources are limited. Consequently, the slow adoption of cutting-edge tissue diagnostics in certain areas restricts the availability of accurate diagnostic tools for patients, impeding overall market growth in this sector.

Market Trends of the Global Tissue Diagnostics Market

The Global Tissue Diagnostics market is witnessing a significant trend towards personalized healthcare, driven by an increasing emphasis on tailored therapies that cater to individual genetic profiles. This shift reflects the need for advanced diagnostic tools capable of identifying specific biomarkers critical for accurate disease characterization. With advancements in genetic profiling and molecular diagnostics, healthcare professionals are equipped to design customized treatment plans that enhance patient outcomes. Consequently, this demand is propelling innovation within the tissue diagnostics sector, as stakeholders strive to develop more precise and effective diagnostic technologies, ultimately leading to improved patient care and a more targeted approach to treatment.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technology Analysis

Global Tissue Diagnostics Market Size by Product Type & CAGR (2025-2032)

• Market Overview
• Consumables
  • Antibodies
  • Kits
  • Reagents
  • Probes
• Instruments
  • Slide-staining Systems
  • Scanners
  • Tissue-processing Systems
  • Other Instruments

Global Tissue Diagnostics Market Size by Technology & CAGR (2025-2032)

• Market Overview
• Immunohistochemistry
• In Situ Hybridization
• Primary & Special Staining
• Anatomic Pathology
• Molecular Pathology
• Digital Pathology & Workflow Management
• Special Staining

Global Tissue Diagnostics Market Size by Disease Type & CAGR (2025-2032)

• Market Overview
• Breast Cancer
• Gastric Cancer
• Lymphoma
• Prostate Cancer
• Non-small Cell Lung Cancer
• Others

Global Tissue Diagnostics Market Size by Modality & CAGR (2025-2032)

• Market Overview
• Clinical
• Pharma / CRO / Research Market

Global Tissue Diagnostics Market Size by End-user & CAGR (2025-2032)

• Market Overview
• Hospitals
• Research Laboratories
• Pharmaceutical Companies
• Contract Research Organizations (CROs)
• Others

Global Tissue Diagnostics Market Size & CAGR (2025-2032)

• North America (Product Type, Technology, Disease Type, Modality, End-user)
  • US
  • Canada
• Europe (Product Type, Technology, Disease Type, Modality, End-user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Technology, Disease Type, Modality, End-user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Technology, Disease Type, Modality, End-user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Technology, Disease Type, Modality, End-user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bioMerieux SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (BD) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioGenex Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cell Signaling Technology, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio SB (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DiaGenic ASA (Norway)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujirebio Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tecan Group Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• STRATEC SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seegene Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Leica Biosystems (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations